Ultimovacs Asa

Good afternoon and welcome to Ultimovax third quarter 2024 business update and financial results. My name is Carlos de Souza and I'm the CEO. And as usual I have with me Jens Björheim, our Chief Medical Officer, and Hans-Fastgård Eide, our Chief Financial Officer. If we can move to the next slide, just to show you briefly our disclaimer, and we continue to the next slide. So I will make a brief introduction. We will talk then about the clinical update for UV1, brief words about our novel drug conjugation platform, the financial update and the news flow. So if we can move to the next slide, this quarter was again, we had the disappointing news about the results from our focus trial

in

head

and neck cancer. We knew that, it was a difficult target to have a framework response measure to improve support and the medical side for cell cancer by technology. a very difficult cancer to

treat, and even the standard of care is very low efficacy. But anyway, we were still disappointed, but as a company, we are still committed to bringing UV1 across the next important data point. That is a DoVac readout that we expect in the first half of 2025. The good news is that DoVac is enrolling patients quite nicely, 28 patients in the last quarter. And this good inclusion of patients is a good sign and again, help us for the time being to keep the expected results in the first half of next year. We also, in September, to communicate it, we stopped the recruitment of patients for the LUNVAC trial in lung cancer. And this discontinuation was due to the very slow rate of patient enrollment in the study. Anyway, the patients will be

analyzed and the results are expected in the first half of 2025. So, we are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. We are still in the process of developing a new model of lung cancer. SUBSCRIBE

clinical update on the UV1 program. So on the next slide you can see the clinical trials that we have conducted and is finalized and those that are still running. Our main indication is as you know melanoma and we have been part of four other trials in different indications. This is

for background information. Moving on to the next slide.

This trial is actively recruiting patients. The trial is in women with a bracket negative or varying cancer, high grade and it's treated in combination with the Durvalumab and Olaparib. As of now 148 patients are included in this trial and the total number should be 184. We expect readout of this trial in the first half of 2025. In the Lungbak trial we stopped the recruitment in that trial in September. It's a trial in non

-small cell lung cancer where the UV1 wax The 31 patients will come first half of next year. So for all those patients that are in the trial, prior to the stop of the recruitment, Next slide. Moving on to the

next drug conjugation platform. Some bullets on that one as well if you go to the next slide. So we are as Carlos mentioned continuing to evaluate our conjugation technology. This is a technology that was originally developed to expand our vaccine pipeline. This is something that the CMC and research group in Ultimax has worked on for several years.

This conjugation technology